Patent details

92773 Product Name: "Sécukinumab"

Basic Information

Publication number:
92773
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP047542345
Legal Status:
Invalid
Application number:
92773
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/14/980 - Cosentyx - sécukinumab
Marketing Authorization Type:
Marketing Authorization Date:
15/01/2015
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
13/07/2015
First Marketing Authorization date:
15/01/2015
Grant date:
14/09/2015
Activation date:
Publication date:
14/09/2015
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
02/06/2029
SPC Extension Expiration:
02/06/2029
Rejection date:
Withdrawal date:

Owner

From:
13/07/2015
 
 

Name:
GENENTECH, INC.
Address:
1 DNA WAY, SOUTH SAN FRANCISCO CA 94080-4990, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
13/07/2015
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
ARNOTT David
Address:
United States (US)

2

Name:
HASS Philip
Address:
United States (US)

3

Name:
LEE James
Address:
United States (US)

4

Name:
GURNEY Austin
Address:
United States (US)

5

Name:
WU Yan
Address:
United States (US)

Publication

Bulletin

Bulletin Heading:
VRV
Bulletin edition number:
2020/09
Publication date:
04/08/2020
Description:
Section L: Applications for patents or supplementary protection certificates which have been withdrawn or are deemed to have been withdrawn (art. 32, 35.1, 39.5 of the law) Renunciation to a patent or supplementary protection certificate (Art. 72 of the law) Rejected applications for extensions for pediatric use of supplementary protections certificates

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
20/04/2020 Outgoing Correspondence 1
20/04/2020 Incoming Correspondence (Post) 9